Validation of a microsphere-based immunoassay for detection of anti-West Nile virus and anti-St. Louis encephalitis virus immunoglobulin M antibodies

被引:27
作者
Johnson, Alison J.
Cheshier, Ronald C.
Cosentino, Giorgio
Masri, Heather P.
Mock, Valerie
Oesterle, Rebecca
Lanciotti, Robert S.
Martin, Denise A.
Panella, Amanda J.
Kosoy, Olga
Biggerstaff, Brad J.
机构
[1] US Dept Hlth & Human Serv, DVBID, Natl Ctr Zoonot Vector Borne & Enteric Dis, Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA
[2] Arizona Dept Hlth Serv, Bur State Lab Serv, Phoenix, AZ 85007 USA
[3] Calif Dept Hlth Serv, Viral & Rickettsial Dis Lab, Richmond, CA USA
[4] Commonwealth Virginia Div Consolidated Lab Serv, Richmond, VA USA
[5] Michigan Dept Community Hlth, Lansing, MI USA
[6] Florida Dept Hlth Lab, Jacksonville, FL USA
关键词
D O I
10.1128/CVI.00115-07
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A microsphere-based immunoassay (MIA) was previously developed that is capable of determining the presence of anti-West Nile (WN) virus or anti-St. Louis encephalitis (SLE) virus immunoglobulin M (IgM) antibodies in human serum or cerebrospinal fluid. The original data set on which the classification rules were based comprised 491 serum specimens obtained from the serum bank at the Division of Vector-Borne Infectious Diseases of the Centers for Disease Control and Prevention (DVBID). The classification rules were used to provide a result and to determine whether confirmatory testing was necessary for a given sample. A validation study was coordinated between the DVBID and five state health laboratories to determine (i) the reproducibility of the test between different laboratories, (ii) the correlation between the IgM-enzyme-linked immunosorbent assay (MAC-ELISA) and the MIA, and (iii) whether the initial nonspecific parameters could be refined to reduce the volume of confirmatory testing. Laboratorians were trained in the method, and reagents and data analysis software developed at the DVBID were shipped to each validating laboratory. Validating laboratories performed tests on approximately 200 samples obtained from their individual states, the collections of which comprised approximately equal numbers of WN virus-positive and -negative samples, as determined by MAGELISA. In addition, 377 samples submitted to the DVBID for arbovirus testing were analyzed using the MIA and MAGELISA at the DVBID only. For the specimens tested at both the state and the DVBID laboratories, a correlation of results indicated that the technology is readily transferable between laboratories. The detection of IgM antibodies to WN virus was more consistent than detection of IgM antibodies to SLE virus. Some changes were made to the analysis software that resulted in an improved accuracy of diagnosis.
引用
收藏
页码:1084 / 1093
页数:10
相关论文
共 23 条
[11]   Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections [J].
Martin, DA ;
Muth, DA ;
Brown, T ;
Johnson, AJ ;
Karabatsos, N ;
Roehrig, JT .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (05) :1823-1826
[12]   Evaluation of a diagnostic algorithm using immunoglobulin M enzyme-linked immunosorbent assay to differentiate human West Nile virus and St. Louis encephalitis virus infections during the 2002 West Nile virus epidemic in the United States [J].
Martin, DA ;
Noga, A ;
Kosoy, O ;
Johnson, AJ ;
Petersen, LR ;
Lanciotti, RS .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (06) :1130-1133
[13]   Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States [J].
Martin, DA ;
Biggerstaff, BJ ;
Allen, B ;
Johnson, AJ ;
Lanciotti, RS ;
Roehrig, JT .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2002, 9 (03) :544-549
[14]   Sequencing and comparative analysis of flagellin genes fliC, fljB, and flpA from Salmonella [J].
McQuiston, JR ;
Parrenas, R ;
Ortiz-Rivera, M ;
Gheesling, L ;
Brenner, F ;
Fields, PI .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (05) :1923-1932
[15]   Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen [J].
Monath, TP ;
Guirakhoo, F ;
Nichols, R ;
Yoksan, S ;
Schrader, R ;
Murphy, C ;
Blum, P ;
Woodward, S ;
McCarthy, K ;
Mathis, D ;
Johnson, C ;
Bedford, P .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (08) :1213-1230
[16]  
MONATH TP, 1987, AM J TROP MED HYG, V37, P40
[17]   Use of sentinel laboratories by clinicians to evaluate potential bioterrorism and emerging infections [J].
Pien, BC ;
Saah, JR ;
Miller, SE ;
Woods, CW .
CLINICAL INFECTIOUS DISEASES, 2006, 42 (09) :1311-1324
[18]   Using expanded genetic alphabets to simplify high-throughput genetic testing [J].
Prudent, JR .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2006, 6 (02) :245-252
[19]  
Ripley B.D., 1996, PATTERN RECOGN
[20]  
*US GOV PRINT OFF, 2005, CTR MED MED SERV DEP, V3